| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.5M | +29.1% | +78.7% |
| R&D Expense | $29K | -72.9% | -70.1% |
| SG&A Expense | $6.8M | -2.9% | +10.3% |
| Operating Income | -$189K | +93.1% | +96.4% |
| Interest Expense | $586K | -1.3% | -42.8% |
| Net Income | -$638K | +79.8% | +88.9% |
| EPS (Basic) | -$0.02 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $21.9M | +17.3% | -45.6% |
| Accounts Receivable | $19.3M | +10.5% | +49.9% |
| Current Assets | $46.1M | +12.9% | -20.5% |
| Total Assets | $49.3M | +9.8% | -16.4% |
| Current Liabilities | $9.8M | +16.7% | +32.0% |
| Long-term Debt |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.5M | — | — |
| Financing Cash Flow | $1.8M | — | — |
| +81.8% |
| +90.5% |
| EPS (Diluted) | -$0.02 | +81.8% | +90.5% |
| $19.4M |
| +0.1% |
| -39.6% |
| Total Liabilities | $53.8M | +2.7% | -16.1% |
| Stockholders' Equity | -$4.5M | +39.8% | +13.1% |